Hovione and Solvias announce a collaboration to improve drug solubility
Combines the strengths of each company
Hovione and Solvias of Switzerland are to collaborate on the development and GMP supply of pharmaceutical co-crystals. No financial details have been revealed.
Portugal-based Hovione says the agreement strengthens its expertise in overcoming drug delivery challenges and also the supply of GMP materials from phase I to commercial scale, combined with Solvias’ solid state chemistry capabilities.
Hovione offers a series of particle engineering technologies focused on amorphous solid dispersions, crystal design and reduction and control of particle size.
The collaboration will give Hovione access to Solvias’ co-crystallisation expertise and capabilities, thus reinforcing and complementing the company’s crystal design solutions to overcome poor bioavailability and other drug delivery challenges.
‘This agreement reinforces our strategy of combining strengths with innovative companies to allow our customers a seamless and integrated approach to their drug delivery challenges,’ said Colin Minchom, Hovione’s vice president of Particle Design.
